These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Pharmacology of cyclooxygenase 2 inhibition]. Beubler E Wien Med Wochenschr; 2003; 153(5-6):95-9. PubMed ID: 12705061 [TBL] [Abstract][Full Text] [Related]
7. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Bertolini A; Ottani A; Sandrini M Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982 [TBL] [Abstract][Full Text] [Related]
8. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]. Blain H; Jouzeau JY; Netter P; Jeandel C Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595 [TBL] [Abstract][Full Text] [Related]
9. Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies. Coruzzi G; Menozzi A; Dobrilla G Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):43-61. PubMed ID: 15032641 [TBL] [Abstract][Full Text] [Related]
10. Selective COX-2 inhibitors and risk of myocardial infarction. Krotz F; Schiele TM; Klauss V; Sohn HY J Vasc Res; 2005; 42(4):312-24. PubMed ID: 15976506 [TBL] [Abstract][Full Text] [Related]
11. The mechanism of action of aspirin. Vane JR; Botting RM Thromb Res; 2003 Jun; 110(5-6):255-8. PubMed ID: 14592543 [TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Meyer-Kirchrath J; Schrör K Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962 [TBL] [Abstract][Full Text] [Related]
14. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Kismet K; Akay MT; Abbasoglu O; Ercan A Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837 [TBL] [Abstract][Full Text] [Related]
15. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs. Everts B; Währborg P; Hedner T Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820 [TBL] [Abstract][Full Text] [Related]
16. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Celotti F; Durand T Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558 [TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibitors--current status and future prospects. Dannhardt G; Kiefer W Eur J Med Chem; 2001 Feb; 36(2):109-26. PubMed ID: 11311743 [TBL] [Abstract][Full Text] [Related]
18. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers]. Ohara M; Sawa T Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696 [TBL] [Abstract][Full Text] [Related]
19. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient]. Galli G; Panzetta G G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419 [TBL] [Abstract][Full Text] [Related]
20. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Venturini CM; Isakson P; Needleman P Curr Opin Nephrol Hypertens; 1998 Jan; 7(1):79-82. PubMed ID: 9442367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]